Oramed Pharmaceuticals Inc. (ORMP) To Present Results From Its Phase 2a FDA Trial With ORMD-0801 At The 2014 Diabetes Summit On April 24, 2014
3/3/2014 7:09:39 AM
JERUSALEM, March 3, 2014 /PRNewswire via COMTEX/ -- JERUSALEM, March 3, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (nasdaqcm:ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by